Journal of Infection and Chemotherapy

, Volume 2, Issue 4, pp 232–239 | Cite as

Efficacy of recombinant human granulocyte-colony stimulating factor alone and in combination with antifungal agents against disseminated trichosporonosis in neutropenic mice

  • Kamberi Perparim
  • Atsuro Hashimoto
  • Masaru Nasu
Original Articles


The ability of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to protect and potentiate the activity of antifungal agents against a lethalTrichosporon beigelii infection in myelosuppressed mice was evaluated in this study. Mice were rendered neutropenic by 2 consecutive-day intraperitoneal injections of cyclophosphamide (200 mg/kg). Recombinant hG-CSF, given subcutaneously at daily doses of 15, 60, and 120 μg/kg for 6 days, shortened the period of neutropenia and increased the number of circulating neutrophils in a dose-dependent manner. When rhG-CSF was administered to neutropenic mice before challenge withT. beigelii (5×106 CFU), it protected against the lethal infection, resulting in improved survival and decreased numbers of fungal cells in the lung, liver, spleen and kidney. However, when the inoculum size increased to 7×106 CFU, a poorer result was obtained using a dose of 60 μg/kg of rhG-CSF, suggesting that the activity of rhG-CSF is dependent on the severity of theT. beigelii infection. Combined with fluconazole (10 mg/kg) or amphotericin B (1 mg/kg), rhG-CSF improved the median survival time from 16 days with fluconazole (59%) and 12 days with amphotericin B (41%) alone to 20 days (93%) and 16 days (55%) in neutropenic mice treated with rhG-CSF plus fluconazole or amphotericin B, respectively. However, the combination of rhG-CSF and itraconazole did not produce significant improvement in survival or clearance of fungal cells from the organs of neutropenic mice. These findings show that rhG-CSF may be a useful immunomodulator againstTrichosporon infections in neutropenic mice and the therapeutic outcome improves when used in combination with fluconazole or amphotericin B.

Key words

trichosporonosis neutropenic mice rhG-CSF antifungal agents 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Haupt HM, Merez GW, Beschorncer EW, Vaughn PW, Saral R. Colonization and infection withTrichosporon species in immunosuppressed hosts. J Infect Dis 1983; 147: 199–203.PubMedGoogle Scholar
  2. 2.
    Hoy J, Hsu KC, Rolston K, Hopfer RL, Luna M, Bodey GP.Trichosporon beigelii infection: a review. Rev Infect Dis 1986; 8: 959–967.PubMedGoogle Scholar
  3. 3.
    Leblond V, Saint-Jean O, Datry A, Lesco G, Frances C, Bellefiqh S, et al. Systemic infection withTrichosporon beigelii (cutaneum). Cancer 1986; 58: 2399–2405.PubMedGoogle Scholar
  4. 4.
    Haupt HM, Merz WG, Beschorner EW, Vaughan WP, Saral R, Walsh TJ, et al. Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 1986; 65: 268–279.Google Scholar
  5. 5.
    Walling DM, McGrawn DJ, Merz WG, Karp JE, Hutchin GM. Disseminated infection withTrichosporon beigeli. Rev Infect Dis 1987; 9: 1113–1119.Google Scholar
  6. 6.
    Walsh TJ. Trichosporonosis. Infect Dis Clin North Am 1989; 3: 43–51.PubMedGoogle Scholar
  7. 7.
    Yung CW, Hanauer SB, Fretzin D, Rippon JW, Shapiro C, Gonzales M. DisseminatedTrichosporon beigelii (cutaneum). Cancer 1981; 48: 2107–2111.PubMedGoogle Scholar
  8. 8.
    Anaissie E, Bodey GP, Kantarjian H, Ro J, Vartivarian SE, Hopfer R, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis 1989; 11: 369–378.PubMedGoogle Scholar
  9. 9.
    Tashiro T, Nagai H, Kamberi P, Goto Y, Kikuchi H, Nasu M, et al. DisseminatedTrichosporon beigelii infection in patients with malignant diseases: immunohistochemical study and review. Eur J Clin Microbiol Infect Dis 1994; 13: 218–224.CrossRefPubMedGoogle Scholar
  10. 10.
    Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough AD, Kelly P, et al.Trichosporon beigelii: an emerging opportunistic pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28: 1616–1622.PubMedGoogle Scholar
  11. 11.
    Gokaslan A, Anaissie E. A novel murine model of disseminated trichosporonosis. Infect Immunol 1992; 8: 3339–3344.Google Scholar
  12. 12.
    Walsh TJ, James WL, Gregory PM, Eileen N, John B, Diano C, et al. ExperimentalTrichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis 1992; 166: 121–133.PubMedGoogle Scholar
  13. 13.
    Anaissie E, Ayse G, Ray H, Robert R, Gregory G, Raida R, et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection and review. Clin Infect Dis 1992; 15: 781–787.PubMedGoogle Scholar
  14. 14.
    Nicola NA, Vadas M. Hematopoietic colony-stimulating factors. Immunol Today 1984; 5: 76–80.CrossRefGoogle Scholar
  15. 15.
    Souza LM, Boone TC, Gabrilove J, Lai HP, Zsebo MK, Murdock CD, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986; 232: 61–65.PubMedGoogle Scholar
  16. 16.
    Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Neutrophil oxidative burst in response to blastoconidia and pseudohyphae ofCandida albicans: augmentation by granulocyte colony-stimulating factor and interferon-α. J Infect Dis 1992; 166: 668–673.PubMedGoogle Scholar
  17. 17.
    Matsumoto M, Matsubara SH, Matsuno T, Tamura M, Hattori K, Nomura H, et al. Trotective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Infect Immun 1987; 55: 2715–2720.PubMedGoogle Scholar
  18. 18.
    Polak A. Protective effect of human granulocyte colonystimulating factor (rhG-CSF) onCandida infections in normal and immunosuppressed mice. Mycoses 1991; 34: 109–118.Google Scholar
  19. 19.
    Nemunaitis J, Meyers JD, Buckner CD, Shannon-Dorcy K, Mouri M, Shulman H, et al. Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 1991; 78: 907–913.PubMedGoogle Scholar
  20. 20.
    Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, Meyers JD, Owens A, Day R, et al. Long-term follow-up of patients with fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993; 82: 1422–1427.PubMedGoogle Scholar
  21. 21.
    Charles RV, John MF, Dale A, Robert JZ, Sharon LA. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat. J Infect Dis 1994; 169: 369–374.Google Scholar
  22. 22.
    Yamamoto Y, Uchida K, Hasegawa T, Friedman H, Klein WT, Yamaguchi H. Recombinant G-CSF induces anti-Candida albicans activity in neutrophil cultures and protection in fungal infected mice. In: Yamaguchi H, Kobayashi SG, Takahashi H (eds.) Recent progress in antifungal chemotherapy. New York: Mancel Deckker, 1991: 309–322.Google Scholar
  23. 23.
    Bodey GP, Anaissie E, Gutterman J, Vadhan S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705–707.PubMedGoogle Scholar
  24. 24.
    Anaissie E, Wong E, Bodey GP, Obrien S, Gutterman J, Vadhan S. Granulocyte-macrophage colony-stimulating factor plus amphotericin B for disseminated mycoses in neutropenic cancer patients. Houston, Texas: ICAAC, 1989 (abstr 73).Google Scholar
  25. 25.
    Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils toAspergillus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61: 1185–93.PubMedGoogle Scholar
  26. 26.
    Polak A. Protective effect of human granulocyte colonystimulating factor (hG-CSF) onCryptococcus andAspergillus infections in normal and immunosuppressed mice. Mycoses 1991; 34: 205–215.Google Scholar
  27. 27.
    Caron AL, Kesley FB, Philip AP, Thomas JW. Response of human polymorphonuclear leukocytes and monocytes toTrichosporon beigelii: host defense against an emerging opportunistic pathogen. J Infect Dis 1994; 170: 157–165.Google Scholar
  28. 28.
    National Committee for Control Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard. Villanova: NCCLS 1992; 12:29, document M27-1.Google Scholar
  29. 29.
    Welte K, Bonilla MA, Gillio AP, Boone CT, Potter KG, Gabrilove JL, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987; 165: 941–948.CrossRefPubMedGoogle Scholar
  30. 30.
    Cohen AM, Hines DK, Korach ES, Ratzkin BJ.In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun 1988; 56: 2861–2865.PubMedGoogle Scholar
  31. 31.
    Pojda Z, Molineux G, Dexter MT. Hemopietic effects of short-term in vivo treatment of mice with various doses of rhG-CSF. Exp Hematol 1990; 18: 27–31.PubMedGoogle Scholar
  32. 32.
    Cohen AM, Zsebo KM, Inoue H, Hines D, Boone TC, Chazin VR, et al. In vivo stimulation of granulopoiesis by recombinant colony-stimulating factor. Proc Natl Acad Sci USA 1987; 84: 2484–2488.PubMedGoogle Scholar
  33. 33.
    Morstyn G, Campbell L, Souza LM, Alton KN, Keech J, Green M, et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988; i: 667–72.Google Scholar
  34. 34.
    Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414–1422.PubMedGoogle Scholar
  35. 35.
    Brounchud MH, Potter MR, Morgenstern G, Blasco MJ, Scarffe JH, Thatcher N, et al.In vitro andin vivo analysis of the effects of recombinant human granulocyte colonystimulating factor in patients. Br J Cancer 1988; 58: 64–69.Google Scholar
  36. 36.
    Kitagawa S, You A, Souza LM, Saito M, Miura Y, Takaku F. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by chemotactic peptide. Biochem Biophys Res Commun 1987; 144: 1143–1146.CrossRefPubMedGoogle Scholar
  37. 37.
    Lyman C, Walsh TJ. Phagocytosis of medically important yeasts by polymorphonuclear leukocytes. Infect Immun 1994; 62: 1489–1493.PubMedGoogle Scholar
  38. 38.
    Djeu YJ, Blanchard KD, Halkias D, Friedman H. Growth inhibition ofCandida albicans by human polymorphonuclear neutrophils: activation by interferon-γ and tumor necrosis factor. J Immunol 1986; 137: 2980–2984.PubMedGoogle Scholar
  39. 39.
    Rex JH, Bennet E, Gallin I, Malech LH, Melnick AD. Normal and deficient neutrophils can cooperate to damageAspergillus fumigatus hyphae. J Infect Dis 1990; 162: 523–528.PubMedGoogle Scholar
  40. 40.
    Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance toAspergillus. J Clin Invest 1982; 69: 617–631.PubMedGoogle Scholar
  41. 41.
    Martino P, Meloni G, Cassone A. Candidal endocarditis and treatment with fluconazole and granulocytemacrophage colony-stimulating factor. Ann Int Med 1990; 112: 966–967.PubMedGoogle Scholar
  42. 42.
    Ohsaka A, Kitagawa S, Sakamoto S, Miura Y, Takanashi N, Takaku F, et al. In vivo activation of neutrophil functions by administration of recombinant granulocyte colony-stimulating factor in patients with malignant lymphoma. Blood 1989; 74: 2743–2748.PubMedGoogle Scholar
  43. 43.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–170.PubMedGoogle Scholar
  44. 44.
    Grauer EM, Bokemeyer C, Bautch W, Freund M, Link H. Successful treatment of aTrichosporon beigelii septicemia in a patient with amphotericin B and granulocyte colonystimulating factor. Infection 1994; 22: 283–286.CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Chemotherapy 1996

Authors and Affiliations

  • Kamberi Perparim
    • 1
  • Atsuro Hashimoto
    • 1
  • Masaru Nasu
    • 1
  1. 1.Second Department of Internal MedicineOita Medical UniversityOitaJapan

Personalised recommendations